Opinion|Videos|January 15, 2025
Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies
Panelists discuss how hepatotoxicity risks vary among second-line primary biliary cholangitis (PBC) treatments, with seladelpar and elafibranor showing favorable hepatic safety profiles compared to obeticholic acid, though all require regular liver function monitoring and dose adjustments based on individual patient response and disease severity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Hepatotoxicity is a key safety concern in PBC treatment. How do therapies like seladelpar, elafibranor, and obeticholic acid compare in terms of hepatotoxicity risk, and what monitoring strategies are recommended?
Advertisement
Related to this article
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Glucose Monitoring: Timing Makes Every Reading Count
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5